Last updated: September 10, 2026
Glycopyrrolate/indacaterol maleate is a once-daily dual bronchodilator combination for chronic obstructive pulmonary disease (COPD), marketed in the United States as Utibron Neohaler by Novartis. Its commercial position has weakened as COPD prescribing shifted toward newer long-acting muscarinic antagonist/long-acting beta2-agonist combinations, inhaler devices, and triple therapies containing an inhaled corticosteroid.
Utibron is a small commercial product relative to Novartis’ larger respiratory brands. Its active pharmaceutical ingredients are established molecules, so the principal intellectual-property value has been concentrated in the combination, inhalation formulation, dose delivery, and device rather than in the underlying compounds.
What is glycopyrrolate and indacaterol maleate?
Glycopyrrolate/indacaterol maleate combines two long-acting bronchodilators:
| Component |
Pharmacology |
Role in COPD |
| Glycopyrrolate |
Long-acting muscarinic antagonist, or LAMA |
Reduces cholinergic bronchoconstriction |
| Indacaterol maleate |
Long-acting beta2-adrenergic agonist, or LABA |
Relaxes airway smooth muscle |
| Product |
Dual LAMA/LABA inhalation therapy |
Maintenance treatment for airflow obstruction |
The U.S. product is delivered through the Neohaler device as a dry-powder inhalation capsule. The FDA approved Utibron Neohaler in October 2015 for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is not indicated for the treatment of acute bronchospasm or asthma.[1]
Novartis also commercialized the same pharmacologic combination outside the United States under the name Ultibro Breezhaler. The U.S. and international products use related active ingredients but differ in branding, device implementation, regulatory labeling, and market access.
What is the FDA regulatory status of Utibron Neohaler?
Utibron Neohaler was approved under a full new drug application rather than a biologic pathway. It therefore faces conventional generic competition, not biosimilar competition.
| Regulatory item |
Status |
| U.S. brand |
Utibron Neohaler |
| Sponsor |
Novartis Pharmaceuticals Corporation |
| NDA |
207930 |
| FDA approval |
October 2015 |
| Dosage form |
Dry-powder inhalation capsule |
| Device |
Neohaler |
| Indication |
Maintenance treatment of COPD |
| Rescue treatment |
Not indicated |
| Regulatory pathway for competitors |
Abbreviated new drug application, subject to product-specific requirements |
The product’s regulatory risk is determined by the FDA’s complex-inhalation-product standards. A competing product must generally demonstrate pharmaceutical equivalence and therapeutic equivalence through requirements covering the active ingredients, strength, dosage form, device, performance, and labeling. Inhaled products can be more difficult to copy than oral tablets, but the market is still exposed to abbreviated new drug application competition after relevant exclusivity and patent barriers expire.
When does glycopyrrolate/indacaterol lose exclusivity?
The practical loss-of-exclusivity date depends on separate FDA regulatory exclusivity and patent rights.
The product received five-year new chemical entity exclusivity only if the FDA determined that the relevant combination or active ingredient qualified under the applicable statutory standard. That period would have ended no later than the early 2020s based on the 2015 approval date. Patent protection, rather than regulatory exclusivity, has been the more important commercial barrier.
The leading patent dates require separation between compound patents, combination patents, and device or formulation patents.
| Protection category |
Commercial relevance |
Indicative timing |
| Glycopyrrolate compound rights |
Limited because glycopyrrolate is an older active ingredient |
Generally expired or commercially weak |
| Indacaterol compound rights |
Historically important to Novartis’ Arcapta and related respiratory franchise |
Core rights reached expiration in the mid-2020s |
| Combination formulation rights |
Covered the co-formulated LAMA/LABA product and inhalation use |
Potentially extended protection beyond individual active ingredients |
| Device and inhaler rights |
Can create product-specific barriers |
Expiration varies by patent family |
| Method-of-use rights |
Cover COPD maintenance use and dosage regimens |
Scope depends on claim construction and labeling |
Public patent records identify Novartis-related U.S. patent families covering indacaterol, glycopyrrolate, pharmaceutical compositions, inhalation formulations, and delivery systems. Patent expiration dates can be affected by patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing practice. A single headline expiration date is therefore insufficient to determine generic launch timing.
What patents protect glycopyrrolate and indacaterol maleate?
The patent estate is layered rather than dependent on one compound patent. Relevant claims may cover:
Active pharmaceutical ingredients
Indacaterol was developed by Novartis as a long-acting beta2 agonist. Historical U.S. patent families associated with indacaterol include patents covering the chemical entity, salts, compositions, and therapeutic use. Glycopyrrolate, by contrast, is an established anticholinergic whose basic compound protection is long expired.
The commercial strength of the active-ingredient estate has therefore been asymmetric. Indacaterol historically supplied greater molecular-level protection, while glycopyrrolate contributed less new-molecule exclusivity.
Combination products
Combination patents may claim:
- Glycopyrrolate and indacaterol in defined molar or weight ratios.
- Dry-powder compositions containing both actives.
- Once-daily dosing.
- Particle-size distributions and carrier systems.
- Stability characteristics.
- COPD maintenance treatment.
- Coordinated delivery from a capsule-based inhaler.
Combination claims are important because a generic applicant may be able to market individual glycopyrrolate or indacaterol products while still facing claims directed to the specific fixed-dose combination.
Formulation and device patents
Inhalation patents can cover:
- Lactose carrier systems.
- Micronized active particles.
- Capsule materials.
- Metered powder quantities.
- Airflow resistance.
- Inhaler geometry.
- Dose deaggregation.
- Patient-use steps.
These rights may not prevent every competing inhaled product, but they can complicate a direct generic substitution using the same dosage form and device architecture.
What is the Orange Book status of Utibron Neohaler?
Utibron Neohaler is an FDA-approved prescription drug listed in the Orange Book under NDA 207930. Orange Book-listed patents can trigger a statutory stay if a generic applicant files a Paragraph IV certification and the brand sponsor brings suit within the prescribed period.
The commercial relevance of an Orange Book patent depends on four factors:
- Whether the patent is listed against the specific NDA.
- Whether the listed claims cover the proposed generic product.
- Whether the generic applicant certifies Paragraph IV or uses another certification pathway.
- Whether the sponsor files litigation within the statutory deadline.
Not every patent associated with the Utibron development program is necessarily Orange Book listed. Patent-family records, FDA listing data, and litigation filings must be assessed separately.
Which companies are challenging glycopyrrolate/indacaterol?
Publicly visible competitive pressure has been stronger from alternative COPD products than from a large, well-established field of direct Utibron generics.
Potential challengers include:
- Generic inhaler manufacturers developing equivalent LAMA/LABA products.
- Authorized or affiliated manufacturers using alternative devices.
- Large respiratory companies with competing dual bronchodilators.
- Companies commercializing triple therapy products that include a LAMA, LABA, and inhaled corticosteroid.
The principal competitive products include:
| Product |
Ingredients |
Company |
Competitive position |
| Utibron Neohaler |
Glycopyrrolate/indacaterol |
Novartis |
Once-daily LAMA/LABA |
| Anoro Ellipta |
Umeclidinium/vilanterol |
GSK |
Once-daily LAMA/LABA |
| Stiolto Respimat |
Tiotropium/olodaterol |
Boehringer Ingelheim |
Once-daily LAMA/LABA |
| Bevespi Aerosphere |
Glycopyrrolate/formoterol |
AstraZeneca |
LAMA/LABA using metered-dose aerosol |
| Duaklir Pressair |
Aclidinium/formoterol |
AstraZeneca and partners |
LAMA/LABA |
| Trelegy Ellipta |
Fluticasone furoate/umeclidinium/vilanterol |
GSK |
Once-daily triple therapy |
The closest branded competitors are Anoro and Stiolto. Bevespi competes more directly on the glycopyrrolate component but uses formoterol rather than indacaterol.
How does Utibron compare with competing COPD drugs?
Utibron’s clinical value comes from once-daily dual bronchodilation without an inhaled corticosteroid. That positioning is relevant for patients who need bronchodilation but do not require, or should not routinely receive, corticosteroid therapy.
Its weaknesses are commercial:
- The Neohaler capsule device requires the patient to load and pierce a capsule.
- Novartis has reduced emphasis on parts of its legacy respiratory portfolio.
- Triple therapies have captured treatment and formulary attention.
- Competing devices may be easier for some patients to use.
- The product lacks the broader escalation pathway of a single-inhaler triple therapy.
Clinical guidelines generally prioritize long-acting bronchodilators for symptomatic COPD and use inhaled corticosteroids selectively based on exacerbation history and eosinophil levels. That supports continued demand for LAMA/LABA treatment, but it does not guarantee share for any specific brand.[2]
What is the market size and revenue exposure?
Novartis does not generally report Utibron revenue as a separately material line item in its consolidated financial disclosures. The brand is grouped within broader respiratory or established-products reporting, making a precise standalone revenue trajectory unavailable from public company filings.
The financial profile can be characterized as follows:
| Driver |
Effect on revenue |
| COPD prevalence and diagnosis |
Supports underlying demand |
| LAMA/LABA guideline use |
Supports category demand |
| Price competition |
Reduces net sales |
| Generic inhaler entry |
Creates sharp erosion risk |
| Triple-therapy substitution |
Limits growth |
| Formulary placement |
Determines access and rebating |
| Device familiarity |
Can support persistence |
| Novartis portfolio prioritization |
Limits promotional investment |
The relevant financial trajectory is therefore more likely to be stable-to-declining rather than growth-oriented. A branded dual bronchodilator can retain revenue in markets with delayed generic entry, but its sales base typically contracts when direct substitutes achieve reimbursement and pharmacy substitution.
What generic launch risks exist?
Generic-entry risk is meaningful even if no large-scale generic launch has displaced Utibron in the United States.
Scenario 1: Delayed direct generic entry
A competitor may wait for the most commercially meaningful patent barriers to expire, then file an ANDA supported by product-specific comparative testing. This would preserve brand revenue temporarily but leave the product vulnerable to a rapid decline after approval.
Scenario 2: Paragraph IV litigation
An ANDA applicant can challenge Orange Book-listed patents through a Paragraph IV certification. Novartis could file infringement litigation, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court action.[3]
Scenario 3: Device-based differentiation
A generic company may seek approval for a therapeutically equivalent product using a different inhaler or a different capsule-and-device configuration. This can reduce literal infringement risk but increase development and regulatory complexity.
Scenario 4: Non-equivalent market substitution
Even without a direct Utibron generic, payers can shift patients to Anoro, Stiolto, Bevespi, or triple therapy. This produces commercial erosion without requiring a legally substitutable generic.
What patent litigation and settlements affect the product?
No major, widely reported U.S. settlement has established a clear authorized-generic launch date for Utibron comparable to settlements involving high-revenue oral products. The absence of a prominent public settlement does not eliminate risk. Inhaled-product litigation may involve confidential licensing, delayed launches, device redesigns, or challenges that remain commercially limited.
The most relevant legal questions are:
- Whether the asserted patent is listed in the Orange Book.
- Whether claims cover the proposed inhaler and capsule.
- Whether the patent claims survive invalidity challenges.
- Whether a court construes the claims narrowly around formulation or device features.
- Whether a settlement permits an earlier launch than patent expiry.
A direct, product-specific litigation event would materially change the launch forecast, but the current commercial case remains driven more by category competition and patent maturation than by a publicly established settlement timetable.
Is there biosimilar risk for glycopyrrolate/indacaterol?
There is no biosimilar risk because Utibron is a small-molecule drug-device combination, not a biologic. The applicable competitive pathway is generic approval through an ANDA or, in some cases, a 505(b)(2) application.
This distinction matters financially. Biosimilar entry often involves clinical comparability and substitution rules that differ from small-molecule generics. Utibron instead faces inhaler-equivalence, formulation, device-performance, labeling, and patent-certification issues.
What manufacturing and intellectual-property barriers remain?
The principal manufacturing barriers are technical rather than molecule-specific.
A competitor must reliably manufacture:
- Micronized glycopyrrolate and indacaterol maleate.
- Consistent powder blends.
- Controlled aerodynamic particle size.
- Stable capsule fills.
- Reproducible dose emission.
- A device that delivers the labeled dose across expected patient airflow.
Inhaled products also face manufacturing controls for contamination, humidity, blend uniformity, and dose-content uniformity. These requirements can delay generic development, but they do not create the same long-term barrier as a protected biologic manufacturing process.
Geographic coverage is fragmented. U.S. patent rights, European patents, and rights in Japan, Canada, China, and emerging markets may expire at different times. Novartis’ international licensing, distribution, and co-commercialization arrangements also vary by jurisdiction. A global launch forecast cannot be inferred from the U.S. patent position alone.
How strong is the patent estate for glycopyrrolate/indacaterol?
The estate is moderate but declining.
| Estate characteristic |
Assessment |
| Novelty of glycopyrrolate |
Weak, because the molecule is old |
| Novelty of indacaterol |
Historically strong, now materially aged |
| Combination protection |
Moderate, depending on claim scope |
| Device protection |
Moderate, with product-specific relevance |
| Formulation protection |
Moderate but technically contestable |
| Regulatory exclusivity |
Expired or no longer the primary barrier |
| Biosimilar barrier |
Not applicable |
| Long-term franchise strength |
Limited without new device or combination innovation |
Novartis’ strongest historical protection came from the indacaterol molecule and the broader respiratory development platform. The value of the Utibron estate now depends on surviving combination, formulation, and device claims rather than on fresh molecular exclusivity.
Key Takeaways
- Glycopyrrolate/indacaterol maleate is a once-daily LAMA/LABA COPD product marketed in the U.S. as Utibron Neohaler.
- Novartis owns the branded product and developed the combination through its respiratory franchise.
- Glycopyrrolate is an old molecule; indacaterol supplied more meaningful historical compound protection.
- The relevant patent estate includes combination, formulation, inhalation, device, and method-of-use claims.
- FDA regulatory exclusivity is no longer the principal commercial barrier.
- Direct generic risk is material, but alternative branded LAMA/LABA and triple-therapy substitution is already a major source of commercial pressure.
- Biosimilar competition does not apply.
- Novartis does not publicly disclose a standalone Utibron revenue line, so precise product-level financial projections cannot be derived from company reporting.
- The product’s financial trajectory is more consistent with maturity and erosion than with sustained growth.
FAQs
What is the brand name for glycopyrrolate and indacaterol maleate?
The U.S. brand name is Utibron Neohaler. The combination is marketed internationally under names including Ultibro Breezhaler.
Is glycopyrrolate/indacaterol a steroid inhaler?
No. It is a dual bronchodilator containing a LAMA and a LABA. It does not contain an inhaled corticosteroid.
Is Utibron the same as Bevespi Aerosphere?
No. Both contain glycopyrrolate, but Utibron combines glycopyrrolate with indacaterol, while Bevespi combines glycopyrrolate with formoterol. The devices also differ.
Can generic manufacturers substitute another LAMA/LABA for Utibron?
Not automatically. A therapeutically equivalent generic must satisfy FDA requirements for the relevant product. A different branded LAMA/LABA is an alternative therapy, not necessarily an interchangeable substitute.
Does Novartis still have a strong COPD position?
Novartis retains respiratory expertise and intellectual property, but Utibron is a mature product facing competition from LAMA/LABA combinations, triple therapies, generic development, and reduced commercial differentiation.
References
- U.S. Food and Drug Administration. (2015). Utibron Neohaler prescribing information.
- Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease: 2024 report.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
- U.S. Patent and Trademark Office. (2024). Patent Center and patent term information.
- Novartis AG. (2023). Annual report 2023.
